Edition:
United Kingdom

Biotechnology & Medical Research

Page 1

Nanorepro Wins DM As New Commercial Partner

9:00am GMT

Dec 18 (Reuters) - NANOREPRO AG ::WINS DM AS NEW COMMERCIAL PARTNER.FOR 2018 EXPECTS AN INCREASE IN SALES OF 40% AND A BALANCED RESULT.

Regeneron And Isa Pharmaceuticals Announce Strategic Immuno-Oncology Collaboration

6:00am GMT

Regeneron Pharmaceuticals Inc ::REGENERON AND ISA PHARMACEUTICALS ANNOUNCE STRATEGIC IMMUNO-ONCOLOGY COLLABORATION.‍REGENERON AND ISA WILL SHARE CLINICAL TRIAL COSTS AND EXCHANGE PRODUCT SUPPLY​.REGENERON PHARMACEUTICALS- CO AND ISA WILL JOINTLY FUND AND CONDUCT CLINICAL TRIALS OF COMBINATION TREATMENT IN CERVICAL CANCER AND HEAD-AND-NECK CANCER.SAYS FURTHER FINANCIAL DETAILS WERE NOT DISCLOSED.REGENERON PHARMACEUTICALS -‍IN ADDITION, CO WILL PROVIDE UPFRONT PAYMENT, EQUITY INVESTMENT IN EXCHANGE FOR OPTION TO EXCLUSIVE GLOBAL LICENSE FOR ISA101​.SAYS ANNOUNCED A CLINICAL COLLABORATION TO ADVANCE ISA101, AN IMMUNOTHERAPY TARGETING HPV16-INDUCED CANCER.

Merrimack Pharmaceuticals Files For Mixed Shelf Of Upto $150 Mln

Friday, 15 Dec 2017

Dec 15 (Reuters) - Merrimack Pharmaceuticals Inc ::MERRIMACK PHARMACEUTICALS INC FILES FOR MIXED SHELF OF UPTO $150 MILLION - SEC FILING.

Navidea Biopharmaceuticals Files For Mixed Shelf Of Upto $100 Mln

Friday, 15 Dec 2017

Dec 15 (Reuters) - Navidea Biopharmaceuticals Inc ::NAVIDEA BIOPHARMACEUTICALS INC FILES FOR MIXED SHELF OF UPTO $100 MILLION - SEC FILING.

Zosano Announces Resignation Of Bruce Steel From Board

Friday, 15 Dec 2017

Dec 15 (Reuters) - Zosano Pharma Corp ::ZOSANO ANNOUNCES RESIGNATION OF BRUCE STEEL FROM BOARD OF DIRECTORS.ZOSANO PHARMA CORP - FOLLOWING STEEL'S RESIGNATION, NUMBER OF BOARD OF DIRECTOR SEATS HAS BEEN REDUCED TO FIVE.

Repros Says Received EMA Feedback That Negative Opinion Is Likely To Be Received In Jan 2018

Friday, 15 Dec 2017

Dec 15 (Reuters) - Repros Therapeutics Inc ::REPROS THERAPEUTICS INC.® RECEIVES FEEDBACK FOLLOWING AN ORAL EXPLANATION WITH THE EUROPEAN MEDICINES AGENCY.REPROS THERAPEUTICS - FOLLOWING ORAL EXPLANATION, HAS RECEIVED FEEDBACK THAT A NEGATIVE OPINION IS LIKELY TO BE RECEIVED IN JANUARY 2018 FROM CHMP.REPROS THERAPEUTICS INC - OPINION IS LIKELY TO BE RECEIVED FROM CHMP FOR CENTRALIZED MAA FOR ENCLOMIPHENE FOR TREATMENT OF SECONDARY HYPOGONADISM.

Trillium Therapeutics Inc Files For Mixed Shelf Of Upto $150 Mln

Friday, 15 Dec 2017

Dec 15 (Reuters) - Trillium Therapeutics Inc ::TRILLIUM THERAPEUTICS INC FILES FOR MIXED SHELF OF UPTO $150 MILLION - SEC FILING.

Verastem Announces Pricing Of Public Offering Of Common Stock

Friday, 15 Dec 2017

Verastem Inc ::VERASTEM ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.VERASTEM INC - ANNOUNCED PRICING OF ITS PREVIOUSLY ANNOUNCED UNDERWRITTEN PUBLIC OFFERING OF APPROXIMATELY $25 MILLION OF SHARES OF ITS COMMON STOCK.

Global Blood Therapeutics Prices A $100.0 Mln Common Stock Public Offering

Friday, 15 Dec 2017

Dec 15 (Reuters) - Global Blood Therapeutics Inc ::GLOBAL BLOOD THERAPEUTICS PRICES A $100.0 MILLION COMMON STOCK PUBLIC OFFERING.

Ultragenyx And Kyowa Kirin Announce Burosumab Receives Positive CHMP Opinion For Treatment Of X-Linked Hypophosphatemia In Children

Friday, 15 Dec 2017

Dec 15 (Reuters) - Ultragenyx Pharmaceutical Inc ::ULTRAGENYX AND KYOWA KIRIN ANNOUNCE BUROSUMAB RECEIVES POSITIVE CHMP OPINION FOR THE TREATMENT OF X-LINKED HYPOPHOSPHATEMIA IN CHILDREN.ULTRAGENYX PHARMA SAYS CHMP'S OPINION IS BEING REFERRED TO EC, FOR FINAL DECISION ON GRANT OF CONDITIONAL MARKETING AUTHORIZATION.ULTRAGENYX PHARMA SAYS DECISION ON GRANT OF CONDITIONAL MARKETING AUTHORIZATION IS EXPECTED IN Q1 2018.

Markets

  • Sectors
  • Europe
  • U.S.
  • Asia

Sector Summary